IBA Receives Down Payment for a Proteus®PLUS System in China

Proton therapy
/
12.08.2021

Five-room proton therapy system including service contract

Louvain-la-Neuve, Belgium, 12 August, 2021 - IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces today that it has received the first payment for a five-room Proteus®PLUS* solution to be installed in China. The receipt of this payment follows the announcement earlier this year that IBA had been selected to supply this solution. The value of this contract for IBA is approximately EUR 90 million and includes a multiyear operation and maintenance agreement.

IBA will equip the new five-room center with four gantry treatment rooms and one fixed beam treatment room. This IBA open platform system will integrate the latest state of the art Proteus®PLUS technologies such as Pencil Beam Scanning (PBS), Cone Beam Computed Tomography (CBCT) and Motion Management (interplay assessment and imaging for moving targets). The platform will be ready for DynamicARC®[1] and ConformalFLASH®[2] delivery modes.

Olivier Legrain, Chief Executive Officer of IBA commented: “We are delighted to add yet another center to the IBA proton therapy community as momentum continues to build globally. This new contract is the 7th Proteus®PLUS solution signed in China and confirms IBA as a distinct leader in the strategically important Chinese proton therapy market. We look forward to bringing this high-quality and much needed cancer treatment to more patients across China.”

 

ENDS

 

About IBA
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,500 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

*Proteus®PLUS is the brand name of Proteus®235

 

 

CONTACTS

Soumya Chandramouli
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com

 

Olivier Lechien
Corporate Communication Director
+32 10 475 890
communication@iba-group.com

 

Consilium Strategic Communications
Amber Fennell, Angela Gray, Lucy Featherstone
+44 (0) 20 3709 5700
IBA@consilium-comms.com


[1] DynamicARC® is a registered brand of the IBA’s Proton Arc therapy solution currently under research and development phase. It will be available for sale when regulatory clearance is received.

[2] ConformalFLASH® is a registered brand of the IBA’s Proton FLASH irradiation solution currently under research and development phase. It will be available for sale when regulatory clearance is received.

Share
Download

Cookies policy

En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies pour vous proposer des services et des offres adaptés à vos centres d’intérêts.

Gérer vos préférences de cookies

Chez IBA, le respect de votre vie privée reste une priorité.

Les cookies fonctionnels garantissent le fonctionnement du site web. Ils ne peuvent pas être désactivés. En réglant vos préférences, vous pouvez activer et désactiver l’utilisation de ces cookies sur notre site web. Ces réglages ne seront valides que sur l’appareil que vous utilisez actuellement.

Cookies policies